Pharmaceutical Technology on MSN
FDA approves Acadia’s Daybue Stix for Rett syndrome
The US Food and Drug Administration has approved Acadia Pharmaceuticals’ Daybue Stix (trofinetide), a dye and ...
Although renowned for dozens of spectacular peaks, Acadia National Park on Mount Desert Island has more than outstanding ...
H.C. Wainwright raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $37 from $32 and keeps a Buy rating on the shares following the ...
Travel + Leisure on MSN
This Easy Hike in Acadia National Park Is One of Its Most Scenic—With Peaceful Forest, a Mirror-like Lake, and Mountain Backdrops
The Jordan Pond Path in Acadia National Park is a scenic 3.3-mile loop with calm shoreline views, views of the famous Bubbles ...
ACADIA Pharmaceuticals generates revenue primarily through the commercialization of NUPLAZID for Parkinson's disease ...
Friends of Acadia estimates the park lost about $1.75M in entry revenue in October 2025 alone, not to mention the first two ...
Acadia Pharmaceuticals Inc. is rated a Buy for its steady NUPLAZID/DAYBUE franchises & pipeline-driven upside potential. Read ...
13d
Bar Harbor businesses fear economic hit as Acadia National Park adds $100 fee for non-US tourists
A new $100 surcharge for non-U.S. visitors to Acadia and other national parks raises alarm among Bar Harbor businesses. BAR ...
Acadia Healthcare stock fell after revising its 2025 outlook due to higher litigation costs stemming from patient-related ...
Acadia Healthcare faces rising legal, insurance, and compliance costs and a Medicaid-heavy payer mix under policy pressure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback